Phosphosignature predicts dasatinib response in non-small cell lung cancer

Molecular and Cellular Proteomics

Volumn 11, Issue 9, 2012, Pages 651-668

  Klammer, Martin ^a   Kaminski, Marc ^a   Zedler, Alexandra ^a   Oppermann, Felix ^a   Blencke, Stephanie ^a   Marx, Sandra ^a   Müller, Stefan ^a   Tebbe, Andreas ^a   Godl, Klaus ^a   Schaab, Christoph ^a,b  

^a Evotec München GmbH Dept of Bioinformatics   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA4 INTEGRIN; BIOLOGICAL MARKER; DASATINIB; PHOSPHOPROTEOME; PROTEOME; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ADHESION; CELL GROWTH; CELL LABELING; CELL VIABILITY; CONTROLLED STUDY; CYTOSKELETON; DISEASE MARKER; DRUG EFFECT; DRUG SENSITIVITY; DRUG TARGETING; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; PREDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; TREATMENT RESPONSE; VALIDATION PROCESS;

BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTEGRIN BETA4; LUNG NEOPLASMS; MASS SPECTROMETRY; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTEOME; PYRIMIDINES; THIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84865802221     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M111.016410     Document Type: Article

References (62)

1. Katzel, J. A., Fanucchi, M. P., and Li, Z. (2009) Recent advances of novel targeted therapy in non-small cell lung cancer. J. Hematol. Oncol. 2, 2
2. Reichert, J. M., and Valge-Archer, V. E. (2007) Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 6, 349-356
3. Ross, J. S., and Fletcher, J. A. (1999) HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am. J. Clin. Pathol. 112, S53-S67
4. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., and Slamon, D. J. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648
5. Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., and Clark, E. (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection. Cancer Res. 67, 2226-2238
6. Dressman, H. K., Berchuck, A., Chan, G., Zhai, J., Bild, A., Sayer, R., Cragun, J., Clarke, J., Whitaker, R. S., Li, L., Gray, J., Marks, J., Ginsburg, G. S., Potti, A., West, M., Nevins, J. R., and Lancaster, J. M. (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol. 25, 517-525
7. Olsen, J. V., Blagoev, B., Gnad, F., Macek, B., Kumar, C., Mortensen, P., and Mann, M. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-648
8. Macek, B., Mann, M., and Olsen, J. V. (2009) Global and site-specific quantitative phosphoproteomics: Principles and applications. Annu. Rev. Pharmacol. Toxicol. 49, 199-221
9. Schaab, C. (2011) Analysis of phosphoproteomics data. Methods Mol. Biol. 696, 41-57
10. Blume-Jensen, P., and Hunter, T. (2001) Oncogenic kinase signalling. Nature 411, 355-365
11. Kaminska, B. (2005) MAPK signalling pathways as molecular targets for anti-inflammatory therapy: From molecular mechanisms to therapeutic benefits. Biochim. Biophys. Acta 1754, 253-262
12. Ferlay, J., Parkin, D. M., and Steliarova-Foucher, E. (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46, 765-781
13. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., and Thun, M. J. (2008) Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96
14. Sharma, K., Weber, C., Bairlein, M., Greff, Z., Kéri, G., Cox, J., Olsen, J. V., and Daub, H. (2009) Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 6, 741-744
15. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader, V., Sweetman, G., Bauer, A., Bouwmeester, T., Hopf, C., Kruse, U., Neubauer, G., Ramsden, N., Rick, J., Kuster, B., and Drewes, G. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044
16. Johnson, F. M., Bekele, B. N., Feng, L., Wistuba, I., Tang, X. M., Tran, H. T., Erasmus, J. J., Hwang, L. L., Takebe, N., Blumenschein, G. R., Lippman, S. M., and Stewart, D. J. (2010) Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 4609-4615
17. Andersen, J. N., Sathyanarayanan, S., Di Bacco, A., Chi, A., Zhang, T., Chen, A. H., Dolinski, B., Kraus, M., Roberts, B., Arthur, W., Klinghoffer, R. A., Gargano, D., Li, L., Feldman, I., Lynch, B., Rush, J., Hendrickson, R. C., Blume-Jensen, P., and Paweletz, C. P. (2010) Pathway-based identification of biomarkers for targeted therapeutics: Personalized oncology with PI3K pathway inhibitors. Sci. Transl. Med. 2, 43ra55
18. Sos, M. L., Michel, K., Zander, T., Weiss, J., Frommolt, P., Peifer, M., Li, D., Ullrich, R., Koker, M., Fischer, F., Shimamura, T., Rauh, D., Mermel, C., Fischer, S., Stückrath, I., Heynck, S., Beroukhim, R., Lin, W., Winckler, W., Shah, K., LaFramboise, T., Moriarty, W. F., Hanna, M., Tolosi, L., Rahnenführer, J., Verhaak, R., Chiang, D., Getz, G., Hellmich, M., Wolf, J., Girard, L., Peyton, M., Weir, B. A., Chen, T. H., Greulich, H., Barretina, J., Shapiro, G. I., Garraway, L. A., Gazdar, A. F., Minna, J. D., Meyerson, M., Wong, K. K., and Thomas, R. K. (2009) Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J. Clin. Invest. 119, 1727-1740
19. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A., and Mann, M. (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1, 376-386
20. Cox, J., and Mann, M. (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367-1372
21. Schaab, C., Geiger, T., Stoehr, G., Cox, J., and Mann, M. (2012) Analysis of high accuracy, quantitative proteomics data in the MaxQB database. Mol. Cell. Proteomics 11, 10.1074/mcp.M111.014068
22. Benjamini Y., H., Y. (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Statist. Soc. B 57, 289-300
23. Harris, M. A., Clark, J., Ireland, A., Lomax, J., Ashburner, M., Foulger, R., Eilbeck, K., Lewis, S., Marshall, B., Mungall, C., Richter, J., Rubin, G. M., Blake, J. A., Bult, C., Dolan, M., Drabkin, H., Eppig, J. T., Hill, D. P., Ni, L., Ringwald, M., Balakrishnan, R., Cherry, J. M., Christie, K. R., Costanzo, M. C., Dwight, S. S., Engel, S., Fisk, D. G., Hirschman, J. E., Hong, E. L., Nash, R. S., Sethuraman, A., Theesfeld, C. L., Botstein, D., Dolinski, K., Feierbach, B., Berardini, T., Mundodi, S., Rhee, S. Y., Apweiler, R., Barrell, D., Camon, E., Dimmer, E., Lee, V., Chisholm, R., Gaudet, P., Kibbe, W., Kishore, R., Schwarz, E. M., Sternberg, P., Gwinn, M., Hannick, L., Wortman, J., Berriman, M., Wood, V., de la Cruz, N., Tonellato, P., Jaiswal, P., Seigfried, T., White, R., and Consortium, G. O. (2004) The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 32, D258-D261
24. Kanehisa, M., and Goto, S. (2000) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28, 27-30
25. Al-Shahrour, F., Arbiza, L., Dopazo, H., Huerta-Cepas, J., Mínguez, P., Montaner, D., and Dopazo, J. (2007) From genes to functional classes in the study of biological systems. BMC Bioinformatics 8, 114
26. Klammer, M., Godl, K., Tebbe, A., and Schaab, C. Identifying differentially regulated subnetworks from phosphoproteomic data. BMC Bioinformatics 11, 351
27. Zhou, Y., Cras-Méneur, C., Ohsugi, M., Stormo, G. D., and Permutt, M. A. (2007) A global approach to identify differentially expressed genes in cDNA (two-color) microarray experiments. Bioinformatics 23, 2073-2079
28. Jensen, L. J., Kuhn, M., Stark, M., Chaffron, S., Creevey, C., Muller, J., Doerks, T., Julien, P., Roth, A., Simonovic, M., Bork, P., and von Mering, C. (2009) STRING 8: A global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 37, D412-D416
29. Abeel, T., Helleputte, T., Van de Peer, Y., Dupont, P., and Saeys, Y. (2010) Robust biomarker identification for cancer diagnosis with ensemble feature selection methods. Bioinformatics 26, 392-398
30. Schölkopf, B., and Smola, A. J. (2002) Learning with Kernels, The MIT Press, Cambridge, MA
31. Geiger, T., Cox, J., Ostasiewicz, P., Wisniewski, J. R., and Mann, M. (2010) Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat. Methods 7, 383-385
32. Ramaswamy, S., Tamayo, P., Rifkin, R., Mukherjee, S., Yeang, C. H., Angelo, M., Ladd, C., Reich, M., Latulippe, E., Mesirov, J. P., Poggio, T., Gerald, W., Loda, M., Lander, E. S., and Golub, T. R. (2001) Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl. Acad. Sci. U.S.A. 98, 15149-15154
33. Hutter, B., Schaab, C., Albrecht, S., Borgmann, M., Brunner, N. A., Freiberg, C., Ziegelbauer, K., Rock, C. O., Ivanov, I., and Loferer, H. (2004) Prediction of mechanisms of action of antibacterial compounds by gene expression profiling. Antimicrob. Agents Chemother. 48, 2838-2844
34. Thuerigen, O., Schneeweiss, A., Toedt, G., Warnat, P., Hahn, M., Kramer, H., Brors, B., Rudlowski, C., Benner, A., Schuetz, F., Tews, B., Eils, R., Sinn, H. P., Sohn, C., and Lichter, P. (2006) Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J. Clin. Oncol. 24, 1839-1845
35. Molinaro, A. M., Simon, R., and Pfeiffer, R. M. (2005) Prediction error estimation: A comparison of resampling methods. Bioinformatics 21, 3301-3307
36. Lange, V., Picotti, P., Domon, B., and Aebersold, R. (2008) Selected reaction monitoring for quantitative proteomics: A tutorial. Mol. Syst. Biol. 4, 222
37. Hüttenhain, R., Malmström, J., Picotti, P., and Aebersold, R. (2009) Perspectives of targeted mass spectrometry for protein biomarker verification. Curr. Opin. Chem. Biol. 13, 518-525
38. Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., Zwahlen, M., Kampf, C., Wester, K., Hober, S., Wernerus, H., Björling, L., and Ponten, F. (2010) Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol. 28, 1248-1250
39. Buettner, R., Mesa, T., Vultur, A., Lee, F., and Jove, R. (2008) Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol. Cancer Res. 6, 1766-1774
40. Shor, A. C., Keschman, E. A., Lee, F. Y., Muro-Cacho, C., Letson, G. D., Trent, J. C., Pledger, W. J., and Jove, R. (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res. 67, 2800-2808
41. Johnson, F. M., Saigal, B., Talpaz, M., and Donato, N. J. (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin. Cancer Res. 11, 6924-6932
42. Dans, M., Gagnoux-Palacios, L., Blaikie, P., Klein, S., Mariotti, A., and Giancotti, F. G. (2001) Tyrosine phosphorylation of the β4 integrin cytoplasmic domain mediates Shc signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes. J. Biol. Chem. 276, 1494-1502
43. Chung, J., Bachelder, R. E., Lipscomb, E. A., Shaw, L. M., and Mercurio, A. M. (2002) Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: A survival mechanism for carcinoma cells. J. Cell Biol. 158, 165-174
44. Dutta, U., and Shaw, L. M. (2008) A key tyrosine (Y1494) in the β4 integrin regulates multiple signaling pathways important for tumor development and progression. Cancer Res. 68, 8779-8787
45. Tagliabue, E., Ghirelli, C., Squicciarini, P., Aiello, P., Colnaghi, M. I., and Ménard, S. (1998) Prognostic value of α6β4 integrin expression in breast carcinomas is affected by laminin production from tumor cells. Clin. Cancer Res. 4, 407-410
46. Lu, S., Simin, K., Khan, A., and Mercurio, A. M. (2008) Analysis of integrin β4 expression in human breast cancer: Association with basal-like tumors and prognostic significance. Clin. Cancer Res. 14, 1050-1058
47. Van Waes, C., Kozarsky, K. F., Warren, A. B., Kidd, L., Paugh, D., Liebert, M., and Carey, T. E. (1991) The A9 antigen associated with aggressive human squamous carcinoma is structurally and functionally similar to the newly defined integrin α6β4. Cancer Res. 51, 2395-2402
48. Hornbeck, P. V., Chabra, I., Kornhauser, J. M., Skrzypek, E., and Zhang, B. (2004) PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation. Proteomics 4, 1551-1561
49. Miki, H., Yamaguchi, H., Suetsugu, S., and Takenawa, T. (2000) IRSp53 is an essential intermediate between Rac and WAVE in the regulation of membrane ruffling. Nature 408, 732-735
50. Yamagishi, A., Masuda, M., Ohki, T., Onishi, H., and Mochizuki, N. (2004) A novel actin bundling/filopodium-forming domain conserved in insulin receptor tyrosine kinase substrate p53 and missing in metastasis protein. J. Biol. Chem. 279, 14929-14936
51. Blomquist, A., Schwörer, G., Schablowski, H., Psoma, A., Lehnen, M., Jakobs, K. H., and Rümenapp, U. (2000) Identification and characterization of a novel Rho-specific guanine nucleotide exchange factor. Biochem. J. 352, 319-325
52. Niu, J., Profirovic, J., Pan, H., Vaiskunaite, R., and Voyno-Yasenetskaya, T. (2003) G Protein betagamma subunits stimulate p114RhoGEF, a guanine nucleotide exchange factor for RhoA and Rac1: Regulation of cell shape and reactive oxygen species production. Circ. Res. 93, 848-856
53. Bergamaschi, D., Samuels, Y., Sullivan, A., Zvelebil, M., Breyssens, H., Bisso, A., Del Sal, G., Syed, N., Smith, P., Gasco, M., Crook, T., and Lu, X. (2006) iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat. Genet. 38, 1133-1141
54. Wu, Q., Ding, W., Mirza, A., Van Arsdale, T., Wei, I., Bishop, W. R., Basso, A., McClanahan, T., Luo, L., Kirschmeier, P., Gustafson, E., Hernandez, M., and Liu, S. (2005) Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target. J. Biol. Chem. 280, 12935-12943
55. Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., and Olivier, M. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28, 622-629
56. Berg, D., Malinowsky, K., Reischauer, B., Wolff, C., and Becker, K. F. (2011) Use of formalin-fixed and paraffin-embedded tissues for diagnosis and therapy in routine clinical settings. Methods Mol. Biol. 785, 109-122
57. Luo, F. R., Yang, Z., Camuso, A., Smykla, R., McGlinchey, K., Fager, K., Flefleh, C., Castaneda, S., Inigo, I., Kan, D., Wen, M. L., Kramer, R., Blackwood-Chirchir, A., and Lee, F. Y. (2006) Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin. Cancer Res. 12, 7180-7186
58. Luo, F. R., Barrett, Y. C., Yang, Z., Camuso, A., McGlinchey, K., Wen, M. L., Smykla, R., Fager, K., Wild, R., Palme, H., Galbraith, S., Blackwood-Chirchir, A., and Lee, F. Y. (2008) Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer Chemother. Pharmacol. 62, 1065-1074
59. Herold, C. I., Chadaram, V., Peterson, B. L., Marcom, P. K., Hopkins, J., Kimmick, G. G., Favaro, J., Hamilton, E., Welch, R. A., Bacus, S., and Blackwell, K. L. (2011) Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. Clin. Cancer Res. 17, 6061-6070
60. Kitteringham, N. R., Jenkins, R. E., Lane, C. S., Elliott, V. L., and Park, B. K. (2009) Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 1229-1239
61. Ostasiewicz, P., Zielinska, D. F., Mann, M., and Wiśniewski, J. R. (2010) Proteome, phosphoproteome, and N-glycoproteome are quantitatively preserved in formalin-fixed paraffin-embedded tissue and analyzable by high-resolution mass spectrometry. J. Proteome Res. 9, 3688-3700
62. Gámez-Pozo, A., Sánchez-Navarro, I., Calvo, E., Díaz, E., Miguel-Martín, M., López, R., Agulló, T., Camafeita, E., Espinosa, E., López, J. A., Nistal, M., and Vara, J. Á. (2011) Protein phosphorylation analysis in archival clinical cancer samples by shotgun and targeted proteomics approaches. Mol. Biosyst. 7, 2368-2374